Understanding GLP-1 Medications: Who Should Avoid Them?

Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

GLP-1 medications have transformed weight loss treatment, with studies showing average weight reductions of 15-22% in clinical trials. However, these powerful compounds carry specific contraindications and safety considerations that make them unsuitable for particular patient populations. Understanding who should avoid GLP-1 therapy is essential for safe, personalized treatment planning.

Absolute Medical Contraindications for GLP-1 Use

Certain medical histories create absolute barriers to GLP-1 therapy that cannot be overcome through dose adjustment or monitoring. Patients with a personal or family history of medullary thyroid carcinoma must completely avoid GLP-1 medications, as animal studies linked these compounds to thyroid C-cell tumors. Additionally, individuals with a history of Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should not pursue GLP-1 treatment due to inherited thyroid cancer risk.

Acute pancreatitis represents another critical contraindication requiring immediate medical review. Patients who have experienced unexplained severe abdominal pain or confirmed acute pancreatitis should discuss GLP-1 safety with their physician before starting therapy. Those with chronic pancreatitis face increased risk of complications, making alternative weight loss strategies more appropriate for their health profile.

Gastrointestinal Conditions That Limit GLP-1 Eligibility

GLP-1 medications slow gastric emptying as part of their weight loss mechanism, which creates challenges for patients with certain digestive disorders. Individuals with severe gastroparesis—delayed stomach emptying—should avoid GLP-1 therapy, as these compounds would worsen their condition and cause severe nausea, vomiting, and nutritional complications. Similarly, patients with a history of gastric bypass surgery or other bariatric procedures may face unexpected interactions between GLP-1 effects and altered anatomy.

Inflammatory bowel disease (IBD) patients, including those with Crohn's disease or ulcerative colitis, require careful evaluation before GLP-1 use. While not absolutely contraindicated, active intestinal inflammation combined with GLP-1's effects on motility may trigger flares or worsen existing symptoms. Patients with uncontrolled celiac disease or persistent malabsorption disorders should explore alternative approaches to weight management.

Pregnancy, Breastfeeding, and Fertility Considerations

GLP-1 medications are not approved for use during pregnancy, and most clinical guidelines recommend discontinuation at least 2-3 months before attempting conception. Animal reproduction studies identified potential risks to fetal development, though human pregnancy data remains limited. Women of childbearing age using GLP-1 therapy should maintain reliable contraception and discuss pregnancy planning with their healthcare provider.

Breastfeeding individuals should avoid GLP-1 medications due to unknown transfer into breast milk and potential effects on nursing infants. Patients who recently stopped GLP-1 therapy should wait adequate time before initiating breastfeeding, guided by their prescribing physician. Those prioritizing family planning may benefit from discussing timing and alternative weight management strategies with their medical team.

Medication Interactions and Thyroid Monitoring Challenges

Patients taking certain medications may experience problematic interactions with GLP-1 compounds that alter drug absorption or effectiveness. Individuals on oral diabetes medications, particularly sulfonylureas, face increased hypoglycemia risk when combined with GLP-1 therapy, requiring dose adjustment or medication switching. Those with kidney disease require careful monitoring, as GLP-1 effects on dehydration and renal perfusion may worsen declining kidney function.

Thyroid hormone replacement therapy patients need consistent monitoring when starting GLP-1 treatment, as weight loss-related changes and altered absorption can shift thyroid medication requirements. Patients with uncontrolled thyroid disease should stabilize their thyroid function before initiating GLP-1 therapy. PlexusDx supports safe treatment initiation through physician collaboration and baseline health assessment to identify potential medication conflicts before therapy begins.

Personal Risk Factors and Genetic Predispositions

Beyond medical contraindications, certain genetic factors influence how patients respond to GLP-1 medications and their appropriateness for individual treatment plans. The PlexusDx Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R genes that predict peptide pathway sensitivity and medication efficacy. Patients with genetic profiles showing minimal GLP-1 receptor activity may achieve suboptimal results, making combination therapies or alternative approaches more effective.

History of suicidal ideation or severe depression requires careful evaluation, as GLP-1 medications are not recommended for patients with active mental health crises. While gastrointestinal side effects typically resolve within weeks, vulnerable patients should delay GLP-1 therapy until psychiatric stability is established. PlexusDx emphasizes comprehensive health screening and physician partnership to ensure every patient receives appropriate, personalized treatment recommendations that account for their complete medical and genetic profile.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I take semaglutide if I have a history of thyroid problems?

History of benign thyroid conditions does not automatically contraindicate GLP-1 use, but personal or family history of medullary thyroid carcinoma or MEN2 syndrome requires absolute avoidance. Patients with thyroid disease should discuss monitoring plans with their physician before starting semaglutide injection therapy at PlexusDx.

What does the PlexusDx Precision Peptide Genetic Test reveal about GLP-1 suitability?

The $99 genetic test ($99 add-on after first month) analyzes 14 pathways and 49 peptides, including GLP1R and GIPR variants that predict your receptor sensitivity to GLP-1 medications. This personalized data helps PlexusDx prescribers determine if semaglutide injection or alternative compounds like tirzepatide may work better for your genetic profile.

How much does semaglutide injection cost at PlexusDx, and does price change with safety concerns?

Compounded Semaglutide Injection starts at $149/month across all commitment tiers—your dose may need to go up, but your price won't. PlexusDx serves all 50 states with no insurance required, and treatment is HSA/FSA eligible, making personalized GLP-1 therapy accessible regardless of contraindication concerns.

Are compounded GLP-1 medications from PlexusDx safe if I have kidney disease?

Patients with kidney disease require careful medical evaluation and baseline lab work before starting any GLP-1 medication, as these compounds affect hydration status and renal perfusion. PlexusDx compounds are prepared by licensed 503A pharmacies and require physician oversight to ensure safe dosing and monitoring for your kidney function level.

Can I use GLP-1 if I'm planning to get pregnant soon?

GLP-1 medications are not recommended during pregnancy or when actively trying to conceive within 2-3 months. Discuss family planning timelines with your PlexusDx-affiliated physician, who can help you safely discontinue therapy and transition to alternative weight management strategies that support your reproductive health goals.

Related Reading

• Do Genetic Tests Help Identify People Who Will Benefit From Glp 1 Medications
• Glp 1 Medications
• Can A Dna Test Reveal If I Will Benefit From Glp 1 Medications
• Maximus Glp 1

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.